| __timestamp | Agios Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 22732000 |
| Thursday, January 1, 2015 | 141827000 | 29245000 |
| Friday, January 1, 2016 | 220163000 | 33206000 |
| Sunday, January 1, 2017 | 292681000 | 31152000 |
| Monday, January 1, 2018 | 1397000 | 10136000 |
| Tuesday, January 1, 2019 | 1317000 | 45546000 |
| Wednesday, January 1, 2020 | 2805000 | 43367000 |
| Friday, January 1, 2021 | 18777000 | 81413000 |
| Saturday, January 1, 2022 | 1704000 | 139304000 |
| Sunday, January 1, 2023 | 9504000 | 192361000 |
| Monday, January 1, 2024 | 4165000 | 159417000 |
Unveiling the hidden dimensions of data
In the ever-evolving biotech industry, understanding cost structures is crucial. Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc. have shown distinct financial trajectories from 2014 to 2023. Halozyme's cost of revenue surged by over 740% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Agios Pharmaceuticals experienced a dramatic 90% drop in costs from its peak in 2017 to 2018, indicating a strategic pivot or operational efficiency. By 2023, Halozyme's costs were nearly double those of Agios, highlighting differing business models. This decade-long analysis offers a window into how these companies navigate financial challenges and opportunities in the competitive biotech landscape. Investors and industry watchers can glean insights into how cost management strategies impact long-term growth and sustainability.
Cost of Revenue: Key Insights for Zoetis Inc. and Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Cytokinetics, Incorporated vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Agios Pharmaceuticals, Inc. vs Galapagos NV